Grandbrothers/iStock Editorial via Getty Images
The US FDA has issued a Complete Response Letter to Outlook Therapeutics (OTLK) for its resubmitted Biologics License Application for ONS-5010/Lytenava (bevacizumab-vikg) for wet age-related macular degeneration. Shares are down ~80% in after-hours trading Wednesday. The agency said that additional information the company provided
Follow us on Google for the latest stock news
Follow us on Google for the latest stock news Micromem Technologies (MMTIF) will proceed with a non-brokered private placement by placing...
Copper had its best year since 2009, fueled by near-term supply tightness and bets that demand for the metal key...
Gold and silver fell on the last trading day of 2025, though both remained on track for the biggest annual...
Valneva (VALN) and the world’s largest vaccine maker, Serum Institute of India, announced on Wednesday that they have mutually agreed...
Global reinsurance giant Swiss Re has decided to significantly reduce its activities in Israel. After doing this in the...
On the final day of 2025, three Israeli renewable energy companies signed deals worth a combined NIS 4.5 billion. ...
Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.
